

Transplantation Proceedings

4 Med 59 247 (1978) 15-3 - 25-8

An Official Publication of

The Transplantation Society

The Latin American Transplantation Society

The Japan Society for Transplantation

The European Society for Organ Transplantation

The Hellenic Transplantation Society

The Canadian Transplantation Society

The Transplantation Society of Australia and New Zealand

The Scandinavian Transplantation Society

Transplantation Proceedings (ISSN 0041-1345) is published bimonthly by Grune & Stratton, Inc., 6277 Sea Harbor Dr, Orlando, FL 32821. Months of issue are February, April, June, August, October, and December. Second class postage paid at Duluth, MN, and at additional mailing offices.

POSTMASTER: Send change of address to *Transplantation Proceedings*, c/o Grune & Stratton, Inc., PO Box 6280, Duluth, MN 55806.

Editorial correspondence should be addressed to Felix T. Rapaport, MD, Department of Surgery, Health Sciences Center, State University of New York at Stony Brook, Stony Brook, NY 11794.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Publisher. The Publisher will not refuse any reasonable request by the author for permission to reproduce any of his or her contributions to the journal.

Correspondence regarding subscriptions or change of address should be addressed to the Publisher, Grune & Stratton, Inc., PO Box 6280, Duluth, MN 55806.

Change of address notices, including both the old and new addresses of the subscriber, should be sent to the Publisher at least one month in advance.

Customer service: (218) 723-9830.

Subscription rates: \$103.00 in the United States and Canada; \$159.00 elsewhere; libraries and institutions, \$139.00 in the United States and Canada; \$159.00 elsewhere. Regular single copies: \$35.00 in the United States and Canada; \$38.00 elsewhere. Special issues and oversize issues are priced according to their actual sizes. Back issue and back volume prices are those in current effect.

Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability. Subscriptions are accepted on a calendar year basis. Journal orders are payable in advance. All prices are subject to change. *Checks* should be sent to Grune & Stratton, Inc., PO Box 6209, Duluth, MN 55806.

The appearance of the code at the bottom of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use, or for the personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per-copy fee through the Copyright Clearance Center, Inc. for copying beyond that permitted by Sections 107 or 108 of the US Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Absence of the code indicates that the material may not be processed through the Copyright Clearance Center, Inc.

Advertising representative: Cunningham Associates, PO Box 308, Park Ridge, NJ, 07656, telephone (201) 767-4170.

Agents for Great Britain: Grune & Stratton Limited, 24-28 Oval Rd, London NW1 7DX, England. Agents for Australia and New Zealand: Grune & Stratton Australia, PO Box 300, North Ryde, NSW 2113, Australia. Publication of an advertisement in *Transplantation Proceedings* does not imply endorsement of its claims by the societies connected with the journal or by the Editors or Publisher of the journal.

Every effort has been made to check generic and trade names, and to verify drug doses. The ultimate responsibility, however, lies with the prescribing physician. Please convey any errors to the Editor(s).

SUMMARIZED CONTENTS

BOOK I

Preface.....	1
I. The State of the Art of Transplantation.....	21
A. Cellular and Molecular Mechanisms.....	23
B. Clinical Transplantation.....	61
C. Immunosuppression.....	121
II. Current Controversies in Transplantation.....	137
III. Progress in Transplantation.....	177
A. Immunobiology.....	179
Regulation of Antigen Expression.....	181
Immunogenic Potential of Graft Components and Various Cell Types.....	239
T Cell Repertoire: Receptors, Subsets, Cell Functions.....	265
Induction of the Transplantation Response.....	296
Recirculation Patterns of White Cells; Generation and Structure of the Inflammatory Response.....	338
Effector Mechanisms of Graft Rejection.....	375
<i>Interactions Between Graft and Inflammatory Cells</i>	375
<i>Isolation and Function of Inflammatory Leukocytes</i>	386
<i>Mechanisms and Inhibition of Target Damage</i>	412
Tolerance and Enhancement.....	446
<i>Induction of Transplantation Tolerance</i>	446
<i>Mechanisms of Transplantation Tolerance</i>	483
<i>Isolation and Function of Suppressor Cells</i>	528
Materno-Fetal Interactions.....	554
Biological Immunosuppression (Experimental).....	568
<i>Immune Sera</i>	568
<i>Monoclonal Antibodies</i>	579
<i>Other Methods</i>	624
Summation of Immunobiology Poster Discussions.....	635
B. Immunogenetics and Histocompatibility.....	639
HLA Matching and Transplant Survival.....	641
Highly Sensitized Recipients.....	716
Immune Reactivity and Transfusions.....	735
Relevance of Crossmatch Findings and Methodology.....	764
<i>Sensitized Patients</i>	764
<i>Antibody Specificity in Sensitized Patients</i>	773
<i>Methods of Crossmatch</i>	789
Molecular Genetics of the Main Histocompatibility Complex.....	811
Immunogenetics and Polymorphism of the Main Histocompatibility Complex.....	839
Posttransplant Immune Reactivity.....	890
Summation of Immunogenetics and Histocompatibility Poster Discussions.....	902

BOOK II

III. Progress in Transplantation (continued)	
C. Experimental Transplantation.....	905
Experimental Transplantation of Islets and Endocrine Tissue.....	907
<i>Pancreatic Islet Isolation</i>	907
<i>Sites of Pancreatic Islet Transplantation</i>	925
<i>Storage and Reduction of Immunogenicity</i>	933
<i>Immunosuppression</i>	946
<i>Results of Pancreatic Islet Transplantation</i>	957
<i>Xenografts and Artificial Pancreas</i>	981
Transplantation of Hepatocytes.....	989

Experimental Pancreas Transplantation.....	1004
<i>Technical Aspects and Sites of Transplantation</i>	1004
<i>Diagnosis and Treatment of Rejection</i>	1023
Experimental Heart and Heart/Lung Transplantation.....	1034
<i>Heart</i>	1034
<i>Heart/Lung; Lung</i>	1043
<i>Diagnosis and Treatment of Rejection</i>	1053
Experimental Liver Transplantation.....	1072
Experimental Transplantation of Kidneys, Composite Tissues, and Other Organs.....	1106
<i>Kidney</i>	1106
<i>Composite Grafts, Intestine, and Neurological Tissue</i>	1115
Experimental Xenografts.....	1137
Mechanism of Action of Cyclosporine and Other Immunosuppressive Drugs.....	1171
<i>Mechanism of Action of Cyclosporine</i>	1171
<i>Other Effects of Cyclosporine</i>	1205
Experimental Use of Cyclosporine.....	1230
<i>Distribution of Toxic Effects</i>	1230
<i>Analogues and Use in Combination With Other Drugs</i>	1265
New Immunosuppressive Drugs.....	1284
<i>Drugs Presumably Affecting Lymphocytes</i>	1284
<i>Drugs Presumably Affecting Macrophages and/or Arachidonic Acid Metabolism</i>	1297
Preservation of Organs.....	1321
<i>Liver</i>	1321
<i>Heart and Lung</i>	1332
<i>Pancreas and Islets</i>	1337
<i>Kidney</i>	1348
Effects of Cyclosporine on Suboptimally Procured Kidneys.....	1382
Experimental Transfusions.....	1407
<i>Blood Constituents</i>	1407
<i>Effects on Graft Survival</i>	1420
<i>Mechanisms of the Transfusion Effect</i>	1429
<i>Transfusion of the Organ Donor</i>	1467
<i>Effects on Tumor Growth</i>	1473
Summation of Experimental Transplantation Poster Discussions.....	1479
D. Clinical Transplantation: Kidney.....	1483
Living Donors.....	1485
<i>Related Donors</i>	1485
<i>Unrelated Donors</i>	1509
Special Donor and Recipient Groups.....	1518
<i>Children</i>	1518
<i>The Aged</i>	1530
<i>Systemic Disease</i>	1535
<i>Blacks</i>	1546
<i>Nondialyzed Recipients</i>	1555
Immunological Monitoring, Graft Histology and Cytology, and Other Diagnostic Methods.....	1559
<i>Immunological Monitoring</i>	1559
<i>Needle Biopsy</i>	1618
<i>Fine Needle Aspiration Biopsy</i>	1641
<i>Urinary Cytology</i>	1662
<i>Other Methods</i>	1667
Pharmacokinetics and Side-Effects of Cyclosporine.....	1695
<i>Pharmacokinetics of Cyclosporine</i>	1695
<i>Nephrotoxicity</i>	1737
<i>Diagnosis of Cyclosporine Nephrotoxicity</i>	1769
<i>Other Side-Effects</i>	1801

BOOK III

III. Progress in Transplantation (continued)

D. Clinical Transplantation: Kidney (continued)

Immunosuppression.....	1833
<i>Cyclosporine</i>	1833
<i>Antilymphocyte Globulins</i>	1874
<i>Monoclonal Antibodies</i>	1898
<i>Triple and Quadruple Drug Combinations</i>	1911
<i>Other Protocols</i>	1961
Conversion of Immunosuppressive Therapy.....	1998
Preservation of Organs and Acute Tubular Necrosis.....	2037
<i>Procurement and Preservation of Organs</i>	2037
<i>Prevention of Acute Tubular Necrosis</i>	2056
<i>Cyclosporine and Early Transplant Function</i>	2074
Chronic Rejection and Long-Term Results.....	2111
Viral Infections.....	2126
<i>Cytomegalovirus and Herpes</i>	2126
<i>Hepatitis (HB_sAG)</i>	2150
<i>Acquired Immune Deficiency (HTLV-LAV) and Epstein Barr Virus</i>	2161
<i>Diagnosis and Prophylaxis</i>	2181
Other Complications.....	2194
<i>Urologic and Nephrologic</i>	2194
<i>Other</i>	2211
Living Related Donors and Specific Transfusion.....	2248
E. Clinical Transplantation: Other Organs	2283
Pancreas and Islet Cell Transplantation.....	2285
<i>Techniques, Results, and Complications</i>	2285
<i>Monitoring and Diagnosis of Rejection</i>	2329
<i>Islet Cell Transplantation</i>	2352
Liver Transplantation.....	2373
<i>Selection of Patients and Results</i>	2373
<i>Operative Procedures</i>	2406
<i>Immunosuppression</i>	2431
<i>Transplantation in Children</i>	2447
<i>Biopsy Findings</i>	2451
Heart and Lung Transplantation.....	2487
<i>Selection of Patients and Results</i>	2487
<i>Heterotopic Heart Transplantation</i>	2512
<i>Immunosuppression</i>	2514
<i>Monitoring</i>	2527
<i>Biopsy Findings</i>	2560
<i>Summation of Clinical Heart Transplantation Poster Discussions</i>	2574
Transplantation of Other Organs.....	2576
Summation of Clinical Transplantation (Other Organs) Poster Discussions.....	2591
F. Bone Marrow Transplantation	2595
Clinical Bone Marrow Transplantation.....	2597
Acute and Chronic Graft-Versus-Host Disease.....	2655
Experimental Bone Marrow Transplantation.....	2707
Bone Marrow Manipulation.....	2735
IV. Transplantation Today and Tomorrow	2763
Author Index.....	2787
Subject Index.....	2807

CONTENTS

BOOK III

IMMUNOSUPPRESSION

Cyclosporine

- Australian Multicentre Trial in Cadaver Renal Transplantation Comparison of Short- and Long-Term Cyclosporine A Therapy With Conventional Therapy
B.M. Hall, A.G.R. Sheil, D.J. Tiller, I. Hardie, J. Mahoney, G. Thatcher, T. Mathew, N. Thompson, and P. Miach 1833
- Risk Factors for Cadaveric Donor Allograft Survival in Cyclosporine-Prednisone-Treated Recipients*B.D. Kahan, R. Mickey, S.M. Flechner, M.J. Lorber, C.A. Wideman, R.H. Kerman, P. Terasaki, and C.T. Van Buren* 1835
- Factors Influencing Kidney Graft Survival in the Cyclosporine Era: A Multivariate Analysis*J. Tiwari, P.I. Terasaki, and M.R. Mickey* 1839
- The Effect of Cyclosporine A in Cadaver Donor Retransplants: A Surprising Effect of the Sex of the Donor.....*J.M. Cecka, J. Cicciarelli, and P.I. Terasaki* 1842
- Cyclosporine Versus Azathioprine in High Risk Cadaver Kidney Transplant Recipients: A Prospective Randomized Study.....*D.J. Norman, P. Wetzsteon, J.M. Barry, and W.M. Bennett* 1845
- The Results of Renal Transplantation With Cyclosporine in Immunologically High-Risk Patients...*R.M. Dickerman, P. Vergne-Marini, J. Langley, G. Trevino, R. Velez, K. Brinker, D. Nesser, D. Long, and A.R. Hull* 1846
- Cyclosporine in Cadaveric Renal Transplantation: A Comparison of Two Immunosuppressive Protocols*M. Koyle, R. Glasscock, J. Rajfer, and H. Ward* 1849
- Does Cyclosporine Eliminate the Need for Preparatory Blood Transfusions?
D.W. Stevens, C.P. Jensen, and L.E. Stevens 1850
- Two-Year Results of a Prospective Randomized Comparison of Cyclosporine/Low Dose Steroid Immunosuppression With Azathioprine and Steroids in Renal Transplantation*C.J. Mieny, P.J. Nel, J.H.R. Becker, and J.P. Pretorius* 1852
- A Prospective Study on the Influence of Cyclosporine and Azathioprine on Renal Allograft Survival and Function*F.C. Henny, A.M.M. Kootte, J.H. Van Bockel, W.M. Baldwin, J. Hermans, B. Bos, L.A. van Es, and L.C. Paul* 1853
- Two-Year Fate of 100 Kidney Transplants Treated With Low-Dose Cyclosporine Without Biopsy Guidelines*G. Civati, E. Del Favero, B. Brando, M.L. Broggi, G. Busnach, D. Forti, L. Belli, and L. Minetti* 1856

(Continued)

CONTENTS

(continued)

- Low-Dose Cyclosporine or Azathioprine One Year After Renal Transplantation
*M.A. Forwell, J.A. Bradley, J.D. Briggs, M.W. Brown, B.J.R. Junor,
S.G. Macpherson, and M.A. Watson* 1858
- Quality of Life on Cyclosporine Versus Conventional Therapy..... *R.G. Simmons
and L.K. Abress* 1860
- Renal Transplantation in Presensitized Patients Treated With Cyclosporine
*D. Albrechtsen, G. Lundgren, A. Bratlie, H. Brynger, I. Fehrmann, L. Frödin,
H. Gäbel, A. Lindholm, and A. Flatmark* 1862
- Primary Cadaveric Renal Transplantation Using Cyclosporine in Patients Over Fifty
Years of Age..... *D.M. Mandelbaum, M.L. Henry, B.G. Sommer,
and R.M. Ferguson* 1863
- A Randomized Study of Cyclosporine With and Without Prednisone in Renal
Allograft Recipients *A.S. MacDonald, P. Daloz, R. Dandavino, S. Jindal,
L. Bear, J.B. Dossetor, J. Klassen, C.R. Stiller, B. Lockwood,
C.E. Reeve, and the Canadian Transplant Group* 1865
- Cyclosporine-Steroids Versus Conventional Therapy in Cadaver Kidney
Transplantation: Analysis of a Randomized Trial at Two Years..... *P. Gianello,
J.P. Squifflet, Y. Pirson, M. Stoffel, Th. Dereme, and G.P.J. Alexandre* 1867
- Cadaveric Renal Transplantation After Pulsatile Perfusion, Histocompatibility
Matching, and Conversion to Cyclosporine Therapy *M. Milgrom,
G.K. Kyriakides, V. Esquenazi, L. Olson, and J. Miller* 1873

Antilymphocyte Globulins

- Superior Renal Allograft Survival and Decreased Rejection With Early High-Dose
and Sequential Multi-Species Antilymphocyte Globulin Therapy *F. Thomas,
P. Cunningham, J. Thomas, U. Gross, D. Gaskins, C. Sash, and K. Parker* 1874
- Sequential Antilymphoblast Globulin and Cyclosporine For Renal Transplantation
B.G. Sommer, M.L. Henry, and R.M. Ferguson 1879
- Place of Antilymphocyte Globulins in the Immunosuppressive Regimen for Kidney
Transplantation *J.L. Touraine, N. Lefrançois, J.M. Dubernard, J.L. Garnier,
J.P. Eygonnet, N. Gibelin, H. Betuel, and J. Traeger* 1881
- Use of Cyclosporine and Minnesota Antilymphoblast Globulin in the Early
Postoperative Treatment of Primary Cadaveric Renal Transplant Recipients
W. Kupin, K.K. Venkat, H.K. Oh, S. Dienst, and N.W. Levin 1882
- Treatment of Acute Rejection Crisis by Antilymphocyte Globulins: A Randomized
Prospective Study in Pediatric Kidney Transplantation..... *M. Broyer, P. Niaudet,
M. Bijaoui, and M-F. Gagnadoux* 1886

(Continued)

CONTENTS

(continued)

- Use of Antithymocyte Globulin and Cyclosporine to Treat Steroid-Resistant Rejection Episodes in Renal Transplant Recipients *A.I. Benvenisty, G.A. Tannenbaum, D.J. Cohen, G. Appel, and M.A. Hardy* 1889
- Antilymphoblast Globulin Treatment of Steroid-Resistant Rejection in Cyclosporine Immunosuppressed Renal Transplant Recipients *V.A. Tellis, A.J. Matas, T.A. Quinn, D. Glicklich, R.J. Weiss, R.J. Soberman, and F.J. Veith* 1892
- Alternative Antirejection Treatment With Steroids or Antilymphoblast Globulin in Renal Transplant Patients Receiving Cyclosporine *S.A. Veremis, M.S. Maddux, R. Pollak, S.S. Kline, and M.F. Mozes* 1893
- Antibody Formation Following Administration of Antilymphocyte Serum
G. Niblack, K. Johnson, T. Williams, W. Green, R. Richie, and R. MacDonell 1896

Monoclonal Antibodies

- Prophylactic Use of an Antilymphocyte Monoclonal Antibody Following Renal Transplantation: A Randomized Controlled Trial *P.J. Friend, R.Y. Calne, G. Hale, H. Waldmann, D.B. Evans, K. Rolles, S. Thiru, and S. Gore* 1898
- The Use of OKT3 to Treat Steroid-Resistant Renal Allograft Rejection in Patients Receiving Cyclosporine *J.R. Thistlethwaite, Jr, B.W. Haag, A.O. Gaber, J.K. Stuart, A.J. Aronson, J.T. Mayes, D.M. Lloyd, and F.P. Stuart* 1901
- Immunosuppression With Monoclonal Anti-T3 Antibody (WT32) in Renal Transplantation *W.J.M. Tax, H.M.W. van de Heijden, H.W. Willems, A.J. Hoitsma, J.H.M. Berden, P.J.A. Capel, and R.A.P. Koene* 1905
- Rescue of Severe Steroid-Resistant Rejection With OKT3.PAN *C. Ponticelli, E. Rivolta, A. Tarantino, A. De Vecchi, and A. Vegeto* 1908
- Anti-T12 Monoclonal Antibody Therapy of Acute Renal Allograft Rejection
E.L. Milford, C.B. Carpenter, R.L. Kirkman, N.L. Tilney, G. Mazoujian, T.B. Strom, J.M. Lazarus, S.F. Schlossman, R.D. Guttman, R. Lowry, L. Rocher, D.A. Campbell, Jr, D.M. Salomon, and W.W. Pfaff 1910

Triple and Quadruple Drug Combinations

- Triple Combination of Low-Dose Cyclosporine, Azathioprine, and Steroids in First Cadaver Donor Renal Allograft..... *D. Fries, C. Hiesse, B. Charpentier, P. Rieu, N. Neyrat, M. Cantarovich, M. Ouziala, J. Bellamy, and G. Benoit* 1911
- Potent Immunosuppression Overcomes Retransplantation, Presensitization, and Historical Positive Crossmatch as Transplant Risk Factors *A.O. Gaber, J.R. Thistlewaite, Jr, B.W. Haag, J. Stuart, J. Mayes, S. Fellner, and F.P. Stuart* 1915

(Continued)

CONTENTS

(continued)

Quadruple Therapy for Cadaver Renal Transplantation.....	<i>M.H. Deierhoi, H.W. Sollinger, M. Kalayoglu, and F.O. Belzer</i>	1917
Triple Drug Therapy: An Alternative Regimen in Renal Transplantation	<i>M.L. Henry, B.G. Sommer, and R.M. Ferguson</i>	1920
Triple and Quadruple Therapy After Renal Transplantation in Patients From Developing Countries	<i>M. Slapak, T. Shell, N. Digard, D.C. Gosling, G. Qerchi della Rovera, R.C. Crockett, and K. Ahmed</i>	1922
Immunosuppression With Cyclosporine, Azathioprine, and Prednisolone in Cadaver Renal Allograft Recipients	<i>R.M. Jones, J.A. Murie, R. Allen, A. Jaskowski, and P.J. Morris</i>	1926
Quadruple Drug Therapy Prevents Graft Loss From Acute Rejection Without Increasing Mortality	<i>J.A. Light, A. Aquino, A. Ali, R. Rodriguez, and S. Ali</i>	1927
Intermodal Immunosuppression for Cadaver Renal Transplantation: Results Using Antilymphocyte Globulin, Azathioprine, Cyclosporine, and Prednisone	<i>P. Halloran, D. Ludwin, R. Bear, M. Aprile, B. McQuarrie, R. Poole, and N. White</i>	1931
A Controlled Prospective Trial of Triple Therapy With Low-Dose Azathioprine, Cyclosporine, and Methylprednisolone in Renal Transplantation	<i>A. De Vecchi, A. Tarantino, G. Montagnino, F. Egidi, A. Vegeto, L. Berardinelli, and C. Ponticelli</i>	1933
A Controlled Trial of Triple Therapy in Renal Transplantation	<i>J.R. Salaman, P.J.A. Griffin, W.B. Ross, and J.D. Williams</i>	1935
Reduction of Nephrotoxicity and Improvement of Immunosuppression by Combination of Cyclosporine A and Azathioprine.....	<i>W.D. Schareck, U.T. Hopt, G.H. Müller, B. Greger, T. Risler, and H. Bockhorn</i>	1937
Decreased Interleukin 2 Production and Increased LEU 2a-Positive Suppressor Cells in Renal Transplant Patients on Triple Therapy with Mizoribine, Cyclosporine A, and Prednisolone	<i>M. Okubo, Y. Kaneko, M. Mizukoshi, K. Inoue, N. Sato, K. Kamata, X-M. Chen, H. Uchida, and T. Endo</i>	1940
A Flexible Immunosuppression Protocol for Organ Transplantation Utilizing Cyclosporine, Azathioprine, and Prednisone	<i>R.T. Schweizer, M. Rovelli, L. Roper, and S.A. Bartus</i>	1944
Cox Regression Analysis of Outcome Risk Factors in 519 Renal Allograft Recipients	<i>D.M. Canafax, S.K. Savik, C.A. Draxler, C.T. Le, N.L. Ascher, W.D. Payne, D.E.R. Sutherland, R.J. Migliori, R.L. Simmons, J.S. Najarian, and D.S. Fryd</i>	1947
Influence of Total Lymphoid Irradiation Plus Cyclosporine on Kidney Graft Outcome in High-Risk Patients.....	<i>R. Cortesini, P. Berloco, A. Famulari, A. Trovati, M. Iappelli, E. Renna Molajoni, A. Bachetoni, R. Pretagostini, G. Marinucci, A. Capua, M. Rossi, and D. Alfani</i>	1949

(Continued)

CONTENTS

(continued)

- Management of Immunosuppressive Problems in Renal Allograft Recipients
*M.I. Lorber, S.M. Flechner, C.T. Van Buren, K. Sorensen, R.H. Kerman,
and B.D. Kahan* 1951
- Immunosuppression With Low-Dose Cyclosporine Combined With Bredinin and
Prednisolone *K. Aso, H. Uchida, K. Sato, K. Yokota, T. Osakabe,
Y. Nakayama, M. Ohkubo, K. Kumano, T. Endo, K. Koshiba,
K. Watanabe, and N. Kashiwagi* 1955
- An Immunosuppressive Protocol Compatible With the United States Kidney
Transplant Diagnosis Related Grouping *F.P. Stuart, J.K. Stuart,
J.R. Thistlethwaite, Jr, A.O. Gaber, and J. Mayes* 1959

Other Protocols

- Pretreatment of Human Renal Allografts With Monoclonal Antibodies to Induce
Long-Term Tolerance *D. Taube, K.I. Welsh, M. Bewick, F.E. Dische,
A. Palmer, V. Parsons, and S. Snowden* 1961
- Results of the South-Eastern Organ Procurement Foundation Strategy for
Transplanting Sensitized Patients..... *R.R. Bollinger, W. Vaughn, F. Sanfilippo,
B. Lucas, W. Lefor, T. Peters, and W. Bias* 1964
- A Randomized Study of Buffy Coat Transfusions in Cadaveric Renal Transplantation
D.J. Norman, L. Fletcher, and J. Barry 1967
- Has Cyclosporine Really Relegated Pretransplant Blood Transfusion to Therapeutic
Obsolescence?..... *J.S. Melzer, R.M. Husing, N.J. Feduska, S.J. Tomlanovich,
F. Vincenti, W.J.C. Amend, M. Garovoy, and O. Salvatierra, Jr* 1971
- Wide Field Low-Dose Total Lymphoid Irradiation in Clinical Kidney Transplantation
*J.A. Myburgh, A.M. Meyers, J.R. Botha, P.D. Thomson, J.A. Smit, S. Browde,
and R. Lakier* 1974
- Comparison of Three Immunosuppressive Regimens in High-Risk Patients:
Immunologic Aspects *E. Renna Molajoni, A. Bachetoni, P. Cinti, F. Sallustio,
M. Rossi, R. Pretagostini, A. Orlandini, P. Berloco, D. Alfani, and R. Cortesini* 1978
- Adverse Effects of Low-Dose Azathioprine on Australian Primary Graft Survival
(1978–1984) *A.P.S. Disney* 1981
- MLR Suppression and MLR-Suppressor Activity Induced by Thoracic Duct Drainage
Prior to Transplantation..... *Y. Ono, S. Ohshima, T. Kinukawa,
O. Matsuura, and S. Hirabayashi* 1985
- Renal Allograft Survival in Highly Sensitized Patients Treated With Cyclosporine
M. Doran, M. Copping, J. Ruth, J. Fish, O. Winsett, and S. Vaidya 1988

(Continued)

CONTENTS

(continued)

- Early Postoperative Monitoring of Natural Anti-A and Anti-B Isoantibodies in ABO-Incompatible Living Donor Renal Allografts *R. Reding, J.P. Squifflet, D. Latinne, M. De Bruyère, Y. Pirson, and G.P.J. Alexandre* 1989
- The Impact of Selected Risk Variables on the Outcome of Renal Transplantation
K.V. Rao, J.H. Andresevic, and A.L. Ney 1991
- Effects of Pretransplant Splenectomy: Univariate and Multivariate Analyses
B.A. Lucas, W.K. Vaughn, F. Sanfilippo, T.G. Peters, and J.W. Alexander 1993
- A Controlled Trial Comparing Sequential Antilymphocyte Sera and Cyclosporine Therapy to Conventional Therapy in Renal Transplant Recipients
C.J. Cardella, M.E. Harding, G.A. deVeber, J. Honey, and G. T. Cook 1996

CONVERSION OF IMMUNOSUPPRESSIVE THERAPY

- Prolonged Cyclosporine Therapy to Induce Solid Engraftment After Renal Transplantation *W. Weimar, D.J. Versluis, G.J. Wenting, F.H.M. Derkx, M.A.D.H. Schalekamp, and J. Jeekel* 1998
- Improvement of Renal Function After Conversion From Cyclosporine Only to Prednisolone-Azathioprine Followed by Late-Onset Graft Failure in Renal Transplant Patients. *A.M. Tegzess, W.J. van Son, J.M. Beelen, W.J. Sluiter, S. Meijer, and M.J.H. Slooff* 2000
- Conversion From Azathioprine and/or Prednisolone to Cyclosporine A in Renal Allograft Recipients *H. Ebel and H. Lange* 2005
- Conversion From Cyclosporine to Azathioprine Improves Renal Function Without Increased Risk of Graft Failure *M.S. Maddux, S.A. Veremis, R. Pollak, and M.F. Mozes* 2007
- Safe Conversion from Cyclosporine..... *P.L. Adams, J.M. Burkart, R.W. Hamilton, W.B. Lorentz, M.C. Browning, J.H. Meredith, and E.R. Heise* 2010
- The Fate of Living Related Donor Kidney Recipients After Conversion From Cyclosporine to Azathioprine..... *T. Oka, Y. Omori, I. Aikawa, T. Yasumura, I. Nakai, and S. Matsui* 2012
- Elective Conversion From Cyclosporine to Azathioprine: Long-Term Follow-Up
P.S. Veitch, J.D. Taylor, J. Feehally, J. Walls, and P.R.F. Bell 2017
- Cyclosporine to Azathioprine Conversion in Cadaveric Renal Transplant
T.A. Gonwa, D.D. Nghiem, and R.J. Corry 2018
- Withdrawal of Methylprednisolone at the Sixth Month in Renal Transplant Recipients Treated With Cyclosporine *L. Cristinelli, G. Brunori, G. Setti, A. Manganoni, A.M. Manganoni, F. Scolari, S. Sandrini, P. Scaini, S. Savoldi, C. Camerini, and R. Maiorca* 2021

(Continued)

CONTENTS

(continued)

Corticosteroid Withdrawal With Substitution of Azathioprine in Cyclosporine-Treated Primary Cadaveric Renal Transplant Recipients	<i>W. Kupin, K.K. Venkat, D. Florence-Green, C. Norris, H.K. Oh, S. Dienst, and N.W. Levin</i>	2024
Stopping Prednisone in Kidney Transplant Recipients Taking Cyclosporine: Safety Conditions.....	<i>J. Lloveras, J. Masramon, A. Orfila, X. Cuevas, and J. Aubia</i>	2027
Effects of HLA Matching and Panel Reactive Antibodies in the Development of Rejection After Conversion of Cyclosporine To Azathioprine.....	<i>S.M. Zemel, S.Y. Shen, M.R. Weir, F.J. Dagher, and F.R. Bentley</i>	2029
Conversion of Cyclosporine to Azathioprine in Renal Transplant Patients	<i>S.Y. Shen, S.M. Zemel, M.R. Weir, F.J. Dagher, and F.R. Bentley</i>	2032

PRESERVATION OF ORGANS AND ACUTE TUBULAR NECROSIS

Procurement and Preservation of Organs

The Value of Hormonal Therapy in Improving Organ Viability in the Transplant Donor	<i>D. Novitzky, D.K.C. Cooper, and B. Reichart</i>	2037
Preservation of the Cortical Renal Microcirculation: A Prerequisite for Immediate Renal Allograft Function	<i>D. Anaise, H. Lehr, H. Atkins, Z. Oster, A. Arnold, W.C. Waltzer, and F.T. Rapaport</i>	2039
Usefulness of Radionuclide Scintiphotography to Evaluate Preserved Kidney Viability	<i>K. Sato, H. Asari, Y. Masaki, M. Uchida, K. Aso, K. Yoda, K. Ishii, D. Anaise, W. Waltzer, and F.T. Rapaport</i>	2043
A Controlled Comparison of Kidney Preservation by Two Methods: Machine Perfusion and Cold Storage	<i>J.E. Heill, D.M. Canafax, D.E.R. Sutherland, R.L. Simmons, M. Dunning, and J.S. Najarian</i>	2046
Preservation Effect on Oligo-anuria in the Cyclosporine Era: A Prospective Trial With 26 Paired Cadaveric Renal Allografts	<i>R. Mendez, R.G. Mendez, N. Koussa, S. Cats, T.P. Bogaard, and U. Khetan</i>	2047
Limiting Factors in Successful Preservation of Cadaveric Kidneys With Ischemia Times Exceeding 50 Hours	<i>G.M. Abouna, M.S. Samhan, M.S.A. Kumar, A.G. White, and O.S.G. Silva</i>	2051

Prevention of Acute Tubular Necrosis

The Effect of Intraoperative Fluid Management of the Incidence of Acute Tubular Necrosis ...	<i>I. Dawidson, P. Peters, A. Sagalowsky, D. Abshier, and L. Coopender</i>	2056
--	--	------

(Continued)

CONTENTS

(continued)

- The Causes and Consequences of Failure of Cadaver Kidneys to Function: A Case-Control Study.....*M. Aprile, P. Halloran, S. Zeldin, P. Brasher, and V. Farewell* 2058
- Successful Long-Term Preservation and Transplantation of Human Cadaveric Kidneys.....*J. Szmidt, M. Karolak, K. Madej, T. Sablinski, S. Frunze, A. Jelonek, and J. Nielubowicz* 2060
- The Influence of Cold Ischemia on the Function of Cadaveric Renal Transplants in Cyclosporine A-Treated Patients.... *Hm. van Goor, R.M.H. Wijnen, W. Geerlings, A.M. Tegzess, and M.J.H. Slooff* 2061
- Important Role for Mannitol in the Prevention of Acute Renal Failure After Cadaveric Kidney Transplantation..... *A.J. Hoitsma, A.F. Groenewoud, J.H.M. Berden, H.J.J. van Lier, and R.A.P. Koene* 2063
- Increased Incidence of Immediate Function After Cadaveric Kidney Transplantation Resulting From Lidocaine Pretreatment of the Donor..... *W. Rowinski, A.O. Gaber, A. Chmura, A. Kobryn, T. Lazowski, A. Zawadzin, T. Orłowski, F. Buckingham, J. Stuart, J. Mayes, J.R. Thistlethwaite, Jr, and F.P. Stuart* 2065
- Prediction of Risk Factors in Acute Tubular Necrosis Following Cadaver Kidney Transplantation..... *J.L. Garnier, A. Mercatello, D. Long, A. Zannier, J.L. Faure, J.L. Touraine, J.F. Moskovichenko, J.M. Dubernard, and J. Traeger* 2068
- Does the Donor Age Influence Graft Survival in Renal Transplantation? *G. Sakellariou, M. Daniilidis, E. Alexopoulos, A. Karagiannis, and M. Papadimitriou* 2071

Cyclosporine and Early Transplant Function

- Improved Early Course After Cadaveric Renal Transplantation by Reducing the Cyclosporine Dose and Adding Azathioprine..... *G. Lundgren, D. Albrechtsen, H. Brynger, A. Flatmark, L. Frodin, H. Gäbel, H. Persson, and C.G. Groth* 2074
- Successful Use of Cyclosporine in Renal Grafts With Prolonged Ischemic Times *R.W.S. Chang, D. Saltissi, A. Al Khader, M. Abomelha, and M. Jawdat* 2080
- The Effect of Cyclosporine on the Early Postoperative Function of Allografted Kidneys With Warm Ischemic Damage..... *S. Ohshima, T. Fujita, H. Asano, and Y. Ono* 2081
- The Effect of Acute Tubular Necrosis on Cyclosporine-Treated Kidney Transplants *O.N. Paramasivan, P.J.A. Griffin, W.B. Ross, and J.R. Salaman* 2085
- Increase in *N*-Acetyl-Beta-Glucosaminidase Excretion as a Marker of Kidney Damage in Cyclosporine-Treated Renal Allografts..... *A.W. Avolio, G. Nanni, F. Citterio, U. Pozzetto, S.C. Magalini, B. Zappacosta, R.M. Tacchino, C. Zuppi, and M. Castagneto* 2086

(Continued)

CONTENTS

(continued)

Effect of Initial Versus Delayed Cyclosporine Therapy in Cadaveric Renal Transplant Patients	<i>R. Lewis, E. Hodge, A. Novick, D. Steinmuller, S. Stroom, R. Cunningham, C. Swift, M. Goormastic, and K. Badhwar</i>	2088
The Long-Term Deleterious Effect of Delayed Graft Function in Cyclosporine-Treated Renal Allograft Recipients.....	<i>L.L. Rocher, C. Landis, D.C. Dafoe, C. Keyserling, R.D. Swartz, and D.A. Campbell, Jr</i>	2093
Significance of Delayed Function in Cyclosporine-Treated Cadaver Kidney Transplants.....	<i>P. Belitsky, A.S. MacDonald, J. Gajewski, J. Boudreau, H. Bitter-Suermann, and A. Cohen</i>	2096
Cyclosporine Immunosuppression and Delayed Graft Function In 455 Cadaveric Renal Transplants	<i>R.J. Taylor, M.D. Landreneau, L. Makowka, T.J. Rosenthal, R.D. Gordon, A.G. Tzakis, T.E. Starzl, and T.R. Hakala</i>	2100
Cyclosporine Immunosuppression and Perfusion Preservation of Cadaver Kidneys	<i>J.W. Bradley, S.I. Cho, A.B. Cosimi, and A.P. Monaco</i>	2104
Impact of Immunosuppressive Regimen on Early Posttransplant Renal Function	<i>J.H. Hong, G.S. Lipkowitz, C.Y. Yen, S.M. Greenstein, T. Manis, and K.M.H. Butt</i>	2106

CHRONIC REJECTION AND LONG-TERM RESULTS

First Kidney Transplants in Children 5 Years of Age or Younger	<i>J.S. Najarian, S.K.S. So, R.L. Simmons, S.M. Mauer, T.E. Nevins, D.E.R. Sutherland, N.L. Ascher, B.M. Chavers, W.D. Payne, and D.S. Fryd</i>	2111
High Long-Term Graft Survival Rates in Kidney Transplantation With the Sequential Association of Antithymocyte Globulin and Cyclosporine A Monotherapy	<i>M. Hourmant, F. Buzelin, P. Dubigeon, and J.P. Soulillou</i>	2113
New Approach to Management of Chronic Vascular Rejection With Prostacyclin Analogue After Kidney Transplantation.....	<i>S. Teraoka, K. Takahashi, H. Toma, T. Yagisawa, Y. Yamaguchi, T. Sanaka, S. Fuchinoue, H. Honda, T. Kawai, K. Tanabe, M. Yasuo, Y. Hayasaka, T. Agishi, and K. Ota</i>	2115
Long-Term Survivor of Kidney Transplantation, Mortality, Rehabilitation, and Immunologic Reactivities.....	<i>H.M. Lee, N. Kenyon, G. Mendez-Picon, and M.P. Posner</i>	2120
Prevention of Chronic Rejection by Cyclosporine and Prednisone	<i>A.N. Arnold, D. Anaise, F. Miller, W.C. Waltzer, and F.T. Rapaport</i>	2122
Promethazine: Results of Triple-Drug Immunosuppression for Kidney Transplantation	<i>T. Orłowski, Z. Gaciong, and L. Pączek</i>	2124

(Continued)

CONTENTS

(continued)

VIRAL INFECTIONS

Cytomegalovirus and Herpes

- The Source of Cytomegalovirus Infection in Seropositive Renal Allograft Recipients Is Frequently the Donor Kidney *J.E. Grundy, M. Super, S. Lui, P. Sweny, and P.D. Griffiths* 2126
- The Clinical Application of a Rapid Diagnostic Test for the Detection of Cytomegalovirus Infection in Renal Transplant Recipients *S.F. Lui, P. Sweny, J.E. Grundy, A. Blaxill, P.D. Griffiths, J.F. Moorhead, and O.N. Fernando* 2129
- Cytomegalovirus Infection in Fifty-Two Renal Transplant Recipients..... *E. Godeaut, N. Galezowski, P. Berche, C. Bonissol, A. Debure, and H. Kreis* 2131
- Interaction Between Cytomegalovirus and *Staphylococcus Aureus* Protein A in Immunoglobulin Secretion and DNA Synthesis *T. Paulin and O. Ringdén* 2133
- Proliferative Response Against Cytomegalovirus and Prognosis of Renal Transplant and IgA Nephropathy Patients *T. Sakamaki, H. Kashiwabara, K. Omori, N. Nagata, T. Hachisu, S. Tateno, H. Shishido, and T. Yokoyama* 2135
- Morbid Outcome of Cytomegalovirus-Negative Transplant Recipients Receiving Cytomegalovirus-Positive Kidneys..... *M.R. Weir, B.C. Irwin, A.W. Maters, G. Genemans, S.Y. Shen, P. Charache, and G.M. Williams* 2137
- Viral Infections in Kidney Transplant Patients Immunosuppressed With Cyclosporine *K. Takahashi, T. Yagisawa, S. Teraoka, H. Toma, T. Agishi, K. Ota, and S. Kobayashi* 2142

Hepatitis (HBs Ag)

- Renal Transplantation in Hepatitis B Surface Antigen-Positive Patients..... *A.G. White, M.S.A. Kumar, O. Strannegard, and G.M. Abouna* 2150
- Prognostic Significance of Hepatitis B Surface Antigenemia in Cadaveric Renal Transplant Patients *E. Rivolta, A. De Vecchi, A. Tarantino, C. Castelnovo, L. Berardinelli, and C. Ponticelli* 2153
- The Influence of Hepatitis B Infection on the Outcome of Renal Allotransplantation *G.L. Flagg, H. Silberman, S.K. Takamoto, and T.V. Berne* 2155
- Hepatitis B and Renal Transplantation..... *D. Scott, A. Mijch, C.R. Lucas, V. Marshall, N. Thomson, and R. Atkins* 2159

(Continued)

CONTENTS

(continued)

Acquired Immune Deficiency (HTLV-LAV) and Epstein-Barr Virus

- Observations Relating to the Incidence of Acquired Immune Deficiency Syndrome and Other Possibly Associated Conditions In a Large Population of Renal Transplant Recipients *N.J. Feduska, H.A. Perkins, J. Melzer, W.J.C. Amend, F. Vincenti, S. Tomlanovich, M. Garovoy, and O. Salvatierra* 2161
- The Value of Human T-Lymphotropic III Screening at the Time of Cross-Match
S.A. Karmi, S.C. Frantz, M.L. Sloan, S.L. Milliken, and T.M. Phillips 2167
- Human T-Lymphotropic Virus III Antibody Screening in Kidney Transplant Recipients and Patients Receiving Maintenance Hemodialysis.... *H-H. Neumayer, W. Fassbinder, S. Kresse, and K. Wagner* 2169
- Investigation of Human T-Lymphotropic Virus III Serology in a Renal Transplant Population.....*R.H. Kerman, S.M. Flechner, C.T. Van Buren, M.I. Lorber, G. Dawson, L. Falk, R. Gutierrez, J.B. Hollinger, and B.D. Kahan* 2172
- HTLV-III/LAV Infection in Kidney and Liver Transplantation *D. Shaffer, R.H. Pearl, R.L. Jenkins, S.M. Hammer, W.J. Dzik, J.E. Groopman, P.N. Benotti, and A.P. Monaco* 2176
- Chronic Epstein-Barr Virus Reactivation After Renal Transplantation:
Immunosuppression With Cyclosporine Versus Azathioprine..... *G. Hillebrand, L.A. Castro, S. Schleibner, W. Land, and J.H. Gurland* 2179

Diagnosis and Prophylaxis

- T Cell Subset Analysis Predicts Virus Infection but not Rejection in Cyclosporine A-Treated Renal Allograft Recipients*H.J. Metselaar, J. Jeekel, Ph.H. Rothbarth, L.M.B. Vaessen, G.J. Wenting, and W. Weimar* 2181
- Cell Cycle Analysis of Activated Mononuclear Blood Cells of Renal Allograft Recipients*A.J. Walle, M. Suthanthiran, Z. Darzynkiewicz, A.L. Rubin, and K.H. Stenzel* 2183
- Monitoring of the Serum Neopterin/Creatinine Ratio in Renal Transplantation
D. Hacini, C. Guerin, P. Berthoux, G. Ville, and F. Berthoux 2185
- Monitoring of Interferon- α_2 -Treated Renal Transplant Patients Using Fine-Needle Aspiration Biopsy *U. Dendorfer, C. Hammer, S. Schleibner, L.A. Castro, G. Hillebrand, W. Land, and W. Brendel* 2187
- Effectiveness of Oral Acyclovir Prophylaxis in Renal Transplant Recipients
M. Stoffel, J.P. Squifflet, Y. Pirson, M. Lamy, and G.P.J. Alexandre 2190

(Continued)

CONTENTS

(continued)

OTHER COMPLICATIONS

Urologic and Nephrologic

- Percutaneous Transluminal Angioplasty: The Procedure of Choice for Renal Allograft Artery Stenosis *S.M. Greenstein, A. Verstandig, G.K. McLean, D.C. DaFoe, D.R. Burke, S.G. Meranze, A. Najji, K.L. Brayman, R.A. Grossman, L.J. Perloff, and C.F. Barker* 2194
- Hemodialysis or Continuous Ambulatory Peritoneal Dialysis Before Transplantation: Prospective Comparison of Clinical and Hemodynamic Outcome
A. Odor-Morales, G. Castorena, C. Jimeno, J.C. Peña, J. Bordes, C. de la Rosa, and F. Chávez-Peón 2197
- Rejection of the Ureter: A New Component of Renal Allograft Rejection *J.P. Katz, A. Hakki, S.M. Katz, and S. Simonian* 2200
- Percutaneous Interventional Radiologic Procedures for Diagnosis and Treatment of Urologic Complications in Renal Transplant Patients *J.J. Warner, T.A.S. Matalon, D.N. Rabin, S.K. Patel, S.C. Jensik, and F.K. Merkel* 2203
- Percutaneous Interventional Procedures in the Management of Urologic Complications of Renal Transplantation *D. Van Gansbeke, C. Matos, P. Gevenoïs, L. De Pauw, J. Struyven, and P. Kinnaert* 2205
- The Incidence of Membranoproliferative Glomerulonephritis in Renal Allografts
M.J. Moritz, J.F. Burke, B.E. Jarrell, and R.A. Carabasi 2206
- Disappearance of Mesangial IgA Deposits From the Kidneys of Two Donors After Transplantation *X. Ceuvas, J. Lloveras, M. Mir, J. Aubia, and J. Masramon* 2208
- Parameters Governing Function in 100 Consecutive Cadaveric Kidney Transplants
K.V. Athersmith, N.J. Digard, B. Gardner, K.R. Harris, G. Venkat-Raman, and M. Slapak 2210

Other

- Cancers Following Cyclosporine Therapy *I. Penn* 2211
- Cancer Incidence in Renal Transplant Patients Treated With Azathioprine or Cyclosporine *A.G.R. Sheil, S. Flavel, A.P.S. Disney, T.H. Mathew, and B.M. Hall* 2214
- Human Antibody Response to Antilymphocytic Preparations in Renal Transplant Patients *C.F. Shield III, A.J. Fucello, P. Marlett, and G. Goldstein* 2217
- Deep Venous Thrombosis After Renal Transplantation *J.A. Murie, R.D. Allen, C.A. Michie, and P.J. Morris* 2219

(Continued)

CONTENTS

(continued)

- Prospective Study and Long-Term Follow-Up of Liver Damage in Renal Transplant Recipients *S. Takahara, H. Ihara, Y. Ichikawa, S. Nagano, T. Fukunishi, T. Sonoda, and Y. Shinji* 2221
- Mechanism of Liver Cell Injury From Iron Overload in Renal Transplant Recipients
K.V. Rao and W.R. Anderson 2225
- Symptomatic Renal Osteodystrophy After Renal Transplantation: Treatment with 1- α -Hydroxycholecalciferol *P.S. Williams, A.N. Hillis, A.J. Carty, R.A. Sells, and J.M. Bone* 2227
- Type II Hyperlipoproteinemia, Hyperapobetalipoproteinemia, and Hyperalphalipoproteinemia Following Renal Transplantation: Prevalence and Precipitating Factors *R.P. Lowry, G. Soltys, R. Mangel, P. Kwiterovitch, and A.D. Sniderman* 2229
- Peptic Ulcer Disease Following Renal Transplantation *S.J. Knechtle, K. Kempf, and R.R. Bollinger* 2233
- Adrenal Function as an Index of the Immunosuppressive Activity of Glucocorticoids (Prednisolone) in Renal Allograft Recipients... *M. Kozaki, T. Hirano, and K. Oka* 2237
- Testicular Histology in Patients Receiving Renal Transplantation *H. Nakamura, M. Takao, K. Nagakura, M. Hata, M. Murai, K. Mukai, and S. Tamai* 2240
- Transmission of Medulloblastoma From Cadaver Donor to Three Organ Transplant Recipients *N. Lefrancois, J.L. Touraine, D. Cantarovich, F. Cantarovich, J.L. Faure, J.M. Dubernard, G. Dureau, J.J. Colpart, R. Bouvier, and J. Traeger* 2242
- Kaposi's Sarcoma After Renal Transplantation *M. Al-Suleiman, A. Haleen, and A. Al Khader* 2243
- Chromosome Aberration in Kidney Transplant Recipients *M. Fukuda, I. Aikawa, Y. Ohmori, N. Yoshimura, I. Naki, S. Matui, and T. Oka* 2245

LIVING RELATED DONORS AND SPECIFIC TRANSFUSION

- Three Year Experience of Donor Specific Transfusion and Concomitant Cyclosporine A *A.N. Hillis, J. Duguid, C.M. Evans, J.M. Bone, and R.A. Sells* 2248
- Optimization of Donor Specific Blood Transfusion in Kidney Transplantation
J.S. Cheigh, M. Suthanthiran, W.T. Stubenbord, M. Fotino, R.R. Riggio, N. Schechter, K.H. Stenzel, and A.L. Rubin 2250
- Donor Specific Transfusions: A Five Year Experience With Alternative Protocols
D.J. Norman, K. Henell, L. Fletcher, and J. Barry 2252
- Kinetics of Antidonor Mixed Lymphocyte Culture Responses in Donor Specific Transfusion Plus Azathioprine-Treated Patients *W.J. Burlingham, A. Grailer, E.M.F. Sparks-Mackety, P.M. Sondel, and H.W. Sollinger* 2255

(Continued)

CONTENTS

(continued)

- Interleukin 2 Response Inhibition Following Donor Specific Transfusions Given With Azathioprine.....*J.D. Tyler, C.B. Anderson, and G.A. Sicard* 2258
- Antiidiotypic Antibody Activity in Patients Receiving Donor Specific Transfusions and Cyclosporine A*K.N. Stewart, D.A. Power, A.N. Hills, and G.R.D. Catto* 2262
- Role of Donor Specific Blood Transfusions in Prolongation of Kidney Graft Survival
T. Matsumoto, K. Sakagami, and K. Orita 2264
- Evaluation of the Risk Factors Associated With Donor Specific Blood Transfusion
S. Vaidya, B.G. Sommer, E.A. Pagel, M. Koegel, and R.M. Ferguson 2268
- The Effects of Donor Specific Transfusion and Cyclosporine A On Graft Outcome
M. Haberal, Z. Oner, N. Aybasi, G. Arslan, M. Turan, and N. Bilgin 2269
- Donor Specific Blood Transfusions Do Not Improve Graft Survival in Living Related Donor Transplantation.....*V.D. Garcia, E.S. Kraemer, C.A. Prompt, A. Santos, J. Caovila, A. Duarte, A.N. Filho, and J.C. Goldani* 2271
- Donor Specific Blood Transfusion in Renal Transplantation: Analysis of 22 Cases
D.H. Casadei, R. Cambariere, H. Leanza, C. Najún Zarazaga, N. Vilá, and L. Cristaldo 2274
- Randomized Clinical Trial of Cyclosporine or Donor Specific Transfusions in High Risk Living-Related Donor Transplantation.....*J. Bordes-Aznar, A. Odor, A. Dib-Kuri, F. Gabilondo, J. Kasep, J.C. Peña, J. Herrera-Acosta, and F. Chávez-Peón* 2276
- Related Donor Kidney Transplantation Is the Best Form of Treatment for Uremia
C.G. Groth, I. Fehrman, O. Ringdén, and G. Lundgren 2278
- Renal Retransplantation From Living Related Donors Using Donor Specific Blood Transfusions*Z. Shapira, A. Yussim, D. Shmueli, A. Mahinson, E. Reichenthal, and C. Servadio* 2280

CLINICAL TRANSPLANTATION: OTHER ORGANS

PANCREAS AND ISLET CELL TRANSPLANTATION

Techniques, Results, and Complications

- Simultaneous Pancreas and Kidney Transplantation: Long Term Results and Comparison of Two Surgical Techniques*J.M. Dubernard, E. La Rocca, A. Gelet, J.L. Faure, D. Long, X. Martin, N.L. Lefrancois, N. Blanc, L. Monti, J.L. Touraine, and J. Traeger* 2285

(Continued)

CONTENTS

(continued)

- Glucose Control After Simultaneous Segmental Pancreas and Kidney Transplantation
*I.G.M. Brons, R.Y. Calne, K. Rolles, P.F. Williams, N.G. Fishwick,
and D.B. Evans* 2288
- Recurrent Diabetic Nephropathy in Renal Allografts Placed in Diabetic Patients and
Protective Effect of Simultaneous Pancreatic Transplantation.....*S-O. Bohman,
H. Wilczek, G. Tydén, G. Jaremko, G. Lundgren, and C.G. Groth* 2290
- Metabolic Control at Two Months to 4.5 Years After Pancreatic Transplantation
With Special Reference to the Role of Cyclosporine..... *G. Tydén, C. Brattström,
R. Gunnarsson, G. Lundgren, L. Öst, J. Östman, and C.G. Groth* 2294
- Quadruple Immunosuppressive Therapy in Whole Pancreas Transplantation
H.W. Sollinger, M. Kalayoglu, R.M. Hoffman, M.H. Deierhoi, and F.O. Belzer 2297
- Use of Recipient Mesenteric Vessels for Revascularization of Segmental Pancreas
Grafts: Technical and Metabolic Considerations ...*D.E.R. Sutherland, F.C. Goetz,
K.C. Moudry, G.M. Abouna, and J.S. Najarian* 2300
- Critical Analysis of Mortality and Graft Loss Following Simultaneous
Renal-Pancreatic Duodenal Transplantation *R.J. Corry, D.D. Nghiem,
B. Schanbacher, and T.A. Gonwa* 2305
- Preservation of Human Pancreatic Allografts in Cold Storage for Six to 24 Hours
G.M. Abouna, D.E.R. Sutherland, G. Florack, J. Heil, and J.S. Najarian 2307
- Evolution of Metabolic and Endocrine Function in Ten Neoprene-Injected Segmental
Pancreas Allografts at Three to 54 Months After Transplantation, Versus
Preliminary Results in Nine Whole Pancreas Allografts With Enteric Diversion
*D. Cantarovich, J. Traeger, E. La Rocca, L.D. Monti, N. Lefrancois,
F. Cantarovich, H. Betuel, N. Blanc-Brunat, J.L. Faure, A. Gelet,
J.M. Dubernard, G. Pozza, and J.L. Touraine* 2310
- A New Variant for Whole Pancreas Grafting..... *G. Kootstra, J.P. van Hooff,
P.J.G. Jörning, K.M.L. Leunissen, C.J. van der Linden, E. Beukers,
and W.A. Buurman* 2314
- Complications of Pancreas Transplantation—Effect of Technique
L.H. Toledo-Pereyra and V.K. Mittal 2319
- Incidence of Fistulas Following Human Pancreas Transplantation—Positive Influence
of Reabsorption of Pancreatic Secretions by the Peritoneum *W-D. Illner,
Th. Gottwald, D. Abendroth, and W. Land* 2323
- Are Late Diabetic Complications Reversible After Pancreas Transplantation? A New
Method of Follow-up of Microcirculatory Changes *D. Abendroth, W-D. Illner,
R. Landgraf, and W. Land* 2325
- Effects of Successful Combined Pancreatic and Renal Transplantation on Advanced
Diabetic Neuropathy: A One-Year Follow-up Study..... *H. Wilczek, G. Solders,
R. Gunnarsson, G. Tydén, and A. Persson* 2327

(Continued)

CONTENTS

(continued)

Monitoring and Diagnosis of Rejection

- Role of Pancreas Graft Biopsies in the Diagnosis and Treatment of Rejection After Pancreas Transplantation *D.E.R. Sutherland, D. Casanova, and R.K. Sibley* 2329
- Studies of the Exocrine Secretion of Segmental Pancreatic Grafts With Special Reference to the Diagnosis of Rejection and to the Penetration of Drugs Into the Pancreatic Juice *C. Brattström, G. Tydén, A.S. Malmborg, G. Lundgren, L. Öst, and C.G. Groth* 2332
- Monitoring of the Pancreatic Allograft by Analysis of Exocrine Secretion *E. Steiner, G. Klima, D. Niederwieser, A. Königsrainer, M. Herold, and R. Margreiter* 2336
- Physiologic Consequences of Pancreatic Allograft Exocrine Drainage Into the Urinary Tract *W.W. Tom, R. Munda, M.R. First, and J.W. Alexander* 2339
- Synchronous Pancreatic and Renal Allografts With Urinary Tract Drainage of the Pancreas *R. Munda, M.A. Weiss, M.R. First, and J.W. Alexander* 2343
- Diagnosis of Rejection in Simultaneous Renal/Pancreas (Urinary Bladder Drained) Transplantation *D.C. Dafoe, D.A. Campbell, Jr, L. Rocher, R. Schwartz, and J.G. Turcotte* 2345
- Rejection in Pancreas Transplantation..... *M. Prieto, D.E.R. Sutherland, L. Fernandez-Cruz, J.B. Heil, and J.S. Najarian* 2348
- Metabolic Monitoring in Renal-Pancreatic Transplants With Urinary Pancreatic Exocrine Diversion *D.D. Nghiem, T.A. Gonwa, and R.J. Corry* 2350

Islet Cell Transplantation

- Results of Cultured Fetal Pancreatic Islet Transplantation in Juvenile Diabetic Patients *Gy. Farkas, S. Karácsonyi, M. Szabo, and G. Kaiser* 2352
- Effect of Human Fetal Pancreas Transplantation on Secretion of C-Peptide and Glucose Tolerance in Type I Diabetics *R.P. Robertson, K.J. Lafferty, C.E. Haug, and R. Weil III* 2354
- Experience With Human Fetal Pancreatic Allografts Over a Three-Year Period *B.E. Tuch, G. Sheil, A.B.P. Ng, and J.R. Turtle* 2357
- Islet Cell Transplantation in Type I Diabetes Mellitus..... *R. Alejandro, D.H. Mintz, J. Noel, Z. Latif, N. Koh, E. Russell, and J. Miller* 2359
- Islet Cell Allo- and Xenotransplantation—Effect of Collagenase-Free Processing and Renal Subcapsular Site *K.O. Bandlien, L.H. Toledo-Pereyra, and D.A. Gordon* 2362
- Intraportal Transplantation of Cryopreserved Human Fetal Pancreata *R. Simonsen, I. Dawidson, S. Aggarwall, K.R. Diller, R. Rajotte, L. Coopender, and D. Abshier* 2365

(Continued)

CONTENTS

(continued)

- Effect of Skin Grafts on Pancreatic Islet Cell Allografts in the Renal Subcapsular Space *J. Amiel, L.H. Toledo-Pereyra, K. Bandlien, D. Gordon, and G. MacKenzie* 2368
- The Principal Results of Pancreatic Islet Cell Culture Transplantation in Diabetes Mellitus Patients *V.I. Shumakov, V.N. Bljumkin, S.N. Ignatenko, N.N. Skaletsky, T.A. Slovesnova, and R.A. Babikova* 2372

LIVER TRANSPLANTATION

Selection of Patients and Results

- Late Mortality and Morbidity After Liver Transplantation.....*S. Iwatsuki, T.E. Starzl, R.D. Gordon, C.O. Esquivel, S. Todo, A.G. Tzakis, L. Makowka, J.W. Marsh, Jr, and C.M. Miller* 2373
- Analysis of Donor Criteria for the Prediction of Outcome in Clinical Liver Transplantation *L. Makowka, R.D. Gordon, S. Todo, N. Ohkohchi, J.W. Marsh, A.G. Tzakis, H. Yokoi, J. Ligush, C.O. Esquivel, M. Satake, S. Iwatsuki, and T.E. Starzl* 2378
- Criteria of Selection for Liver Transplantation.....*D. Samuel, J.P. Benhamou, H. Bismuth, J. Gugenheim, M. Ciardullo, and F. Saliba* 2383
- Immunoprophylaxis of Hepatitis B Virus (HBV) Reinfection in Recipients of Human Liver Allografts *W. Lauchart, R. Müller, and R. Pichlmayr* 2387
- A Positive Lymphocyte Cross-Match and Major Histocompatibility Complex Mismatching Do Not Predict Early Rejection of Liver Transplants in Patients Treated With Cyclosporine *S.B. Moore, R.H. Wiesner, J.D. Perkins, D.M. Nagorney, S. Sterioff, and R.A.F. Krom* 2390
- Development of Class I-Directed Lymphocytotoxic Antibodies After Liver Transplantation *C.F. Bryan, J.T. Newman, R.L. Tillquist, B. Husberg, G.B. Klintmalm, and M.J. Stone* 2392
- Incidence and Outcome of Donor Arterial Anomalies in Liver Allografts *M. Decurtins, P.J. Friend, and R.Y. Calne* 2394
- Orthotopic Liver Transplantation for Secondary Malignancies of the Liver *F. Mühlbacher and F. Piza* 2396
- Incidence of Cytomegalovirus Infection and Its Relationship to Donor-Recipient Serologic Status in Liver Transplantation *J. Rakela, R.H. Wiesner, H.F. Taswell, P.E. Hermans, T.F. Smith, J.D. Perkins, and R.A.F. Krom* 2399

(Continued)

CONTENTS

(continued)

- Tumor Recurrence After Liver Transplantation Followed by High-Dose Cyclophosphamide, Total Body Irradiation, and Autologous Bone Marrow Transplantation for Treatment of Metastatic Liver Disease..... *R. Margreiter, D. Niederwieser, H. Frommhold, D. Schönitzer, A. Gratwohl, and C. Huber* 2403
- Designation of Liver Transplant Centers in the United States..... *N.L. Ascher and R.W. Evans* 2405

Operative Procedures

- Hepatic Artery in Liver Transplantation *S. Todo, L. Makowka, A.G. Tzakis, J.W. Marsh, Jr, F.M. Karrer, M. Armany, C. Miller, M.B. Tallent, C.O. Esquivel, R.D. Gordon, S. Iwatsuki, and T.E. Starzl* 2406
- Vascular Problems in Liver Transplantation..... *G. Blumhardt, B. Ringe, W. Lauchart, M. Burdelski, W.O. Bechstein, and R. Pichlmayr* 2412
- Roux-En-Y Hepatojejunostomy: A Safe Procedure for Biliary Anastomosis in Liver Transplantation *H. Bismuth, D. Castaing, J. Gugenheim, O. Traynor, and M. Ciardullo* 2413
- Experience With Venovenous Bypass in Human Liver Transplantation *B. Ringe, A. Bornscheuer, G. Blumhardt, W.O. Bechstein, K. Wonigeit, and R. Pichlmayr* 2416
- Hemodynamics During Liver Transplantation With Venovenous Bypass
A.W. Paulsen, T.R. Valek, W.S. Blessing, D.D. Johnson, R.I. Parks, J.T. Pyron, M. Ramsay, B.R. Simpson, T. Swygert, P. Walling, and G. Klintmalm 2417
- Selective Bowel Decontamination to Prevent Gram-Negative Bacterial and Fungal Infection Following Orthotopic Liver Transplantation *R.H. Wiesner, P. Hermans, J. Rakela, J. Perkins, J. Washington, S. DiCecco, and R.A.F. Krom* 2420
- Vasopressin Use in Human Liver Transplantation *P.M. Daloze, R. Arnoux, J. Corman, C. Smeesters, G. St Louis, and M. Beaudouin* 2424
- Prognostic Perioperative Factors Predicting the Outcome of Liver Transplantation
P.G. Stock, J.A. Estrin, D.S. Fryd, W.D. Payne, K.G. Belani, B.A. Elick, J.S. Najarian, and N.L. Ascher 2427
- Beneficial Effect of Topical Ice Cooling in Donor Hepatonephrectomy *S.I. Cho, B.P. Zalneraitis, and J.W. Bradley* 2429

Immunosuppression

- A Randomized Clinical Trial Comparing OKT3 and Steroids for Treatment of Hepatic Allograft Rejection..... *A.B. Cosimi, S.I. Cho, F.L. Delmonico, M.M. Kaplan, R.J. Rohrer, and R.L. Jenkins* 2431

(Continued)

CONTENTS

(continued)

- Conversion From Standard Cyclosporine to Low-Dose Cyclosporine and Azathioprine
Therapy as Treatment of Cyclosporine-Related Complications in Liver
Transplant Patients *J.D. Perkins, S. Sterioff, R.H. Wiesner, K.P. Offord,
J. Rakela, E.R. Dickson, and R.A.F. Krom* 2434
- Development of Anti-Idiotypic Antibodies to HLA Antigens in Human Hepatic
Allograft Tolerance *T. Mohanakumar, S.K. Hoover, C. Rhodes,
G. Mendez-Picon, M.W. Flye, and H.M. Lee* 2437
- A Comparison of Azathioprine and Cyclosporine in Liver Transplantation: A Study of
Two Personal Series *R.A.F. Krom, R.H. Wiesner, E.B. Haagsma, J. Ludwig,
C.H. Gips, A.J.K. Grond, and H.J. Houthoff* 2440
- OKT3 in the Reversal of Acute Hepatic Allograft Rejection *C.O. Esquivel,
J.J. Fung, B. Markus, S. Iwatsuki, R.D. Gordon, L. Makowka,
J.W. Marsh, Jr, A.G. Tzakis, S. Todo, and T.E. Starzl* 2443

Transplantation in Children

- Results and Problems in Paediatric Liver Transplantation in the Cambridge/Kings
College Hospital Series: 1968 to July 1986 *N.V. Jamieson, R.Y. Calne,
K. Rolles, N.D. Barnes, and A.P. Mowat* 2447
- Analysis of Current Results of Liver Transplantation in Children *K. Schmidt,
M. Burdelski, U. Bernsau, J. Brodehl, B. Ringe, W. Lauchart, K. Wonigeit,
R. Pichlmayr, and H. Milbradt* 2449

Biopsy Findings

- Use of Triple Therapy and Percutaneous Needle Biopsy to Minimize Graft Failure
Following Liver Transplantation *J.A. St Cyr, B. Elick, D. Freese, H. Sharp,
W. Payne, J. Bloomer, P. Stock, D. Snover, J.S. Najarian,
and N.L. Ascher* 2451
- Orthotopic Liver Transplantation in Humans: Monitoring by Serial Graft Biopsies
F. Saliba, J. Gugenheim, D. Samuel, M. Ciardullo, M. Reynes, and H. Bismuth 2454
- An Analysis of Histological Prognostic Features of Liver Allograft Rejection Based on
270 Serial Biopsies *D.C. Snover, D.K. Freese, J.R. Bloomer, H.L. Sharp,
and N.L. Ascher* 2457
- Histologic Response to OKT3 Therapy for Hepatic Allograft Rejection *R.J. Rohrer,
R.L. Jenkins, U. Khettry, P.N. Benotti, T.F. Dodson, C.G. Karlson, B.A. Georgi,
and A.P. Monaco* 2459
- Correlation of Amino Acid Metabolism and Liver Biopsies in Preoperative and
Postoperative Patients Receiving Hepatic Transplants *G.H.A. Clowes, Jr,
R.H. Pearl, S. Bosari, R.L. Jenkins, and U. Khettry* 2462

(Continued)

CONTENTS

(continued)

- Class I Major Histocompatibility Complex Antigens are Induced on Hepatocytes in Rejecting Human Liver GraftsS.K.S. So, D.C. Snover, N.L. Ascher, and J.L. Platt 2464
- Modified Patterns of Major Histocompatibility Complex-Antigen Expression in Human Liver Grafts During Rejection.....G. Steinhoff, K. Wonigeit, B. Ringe, W. Lauchart, J. Kemnitz, and R. Pichlmayr 2466
- Analysis of T Lymphocytes Infiltrating Human Hepatic Allografts B.H. Markus, J.J. Fung, A. Zeevi, T.E. Starzl, A.J. Demetris, and R.J. Duquesnoy 2470
- Immunohistologic Labeling of Infiltrating T Lymphocytes in Hepatic Allografts: A Rejection Indicator..... J.D. Perkins, R.H. Wiesner, P.M. Banks, N.F. LaRusso, and R.A.F. Krom 2474
- Consequences of Hepatic Artery Pathology After Orthotopic Liver Transplantation E.J. Hesselink, M.J.H. Slooff, K.H. Schuur, Ch. Bijleveld, and Ch. Gips 2476
- Modifications of Biliary and Vascular Basement Membrane Laminin in Serial Hepatic Biopsies After Hepatic Transplantation in Man M. Reynès, V. Tricottet, J.C. Gugenheim, D.J. Hartmann, A.M. Szekely, and H. Bismuth 2478
- Safety and Utility of a Simple Technique of Liver Biopsy Following Liver Transplantation R.J. Jenkins, C.A. Gallik-Karlson, B.A. Georgi, R.J. Rohrer, U. Khettry, P.N. Benotti, T.F. Dodson, R.B. Freeman, and C. Trey 2480
- Diagnosis of Rejection in Liver Transplantation..... K. Hockerstedt, I. Lautenschlager, T.M. Scheinin, J. Ahonen, B. Eklund, P. Häyry, C. Korsbäck, P. Maury, K. Salmela, and E. Taskinen 2483
- Cellular Characteristics of Liver Allograft Rejection..... I. Lautenschlager, H. Höckerstedt, J. Ahonen, B. Eklund, C. Korsbäck, E. Pettersson, K. Salmela, T.M. Scheinin, E. von Willebrand, and P. Häyry 2485

HEART AND LUNG TRANSPLANTATION

Selection of Patients and Results

- The Influence of HLA Matching in Cardiac Allograft Recipients Receiving Cyclosporine and Azathioprine.....M. Yacoub, H. Festenstein, P. Doyle, M. Martin, D. McCloskey, J. Awad, A. Gamba, A. Khaghani, and J. Holmes 2487
- Current Results With Triple Therapy for Heart Transplantation..... R.M. Bolman III, M.T. Olivari, J. Saffitz, R. Sibley, J. Spadaro, C. Cance, and B. Elick 2490
- Cardiac Transplantation in the Sixth Decade of Life S. Szentpetery, M. Thames, J. Hanrahan, J. Morris, and R.R. Lower 2492

(Continued)

CONTENTS

(continued)

A Detailed Study of Cytomegalovirus Infections in the First 160 Heart and Heart/Lung Transplant Recipients at Papworth Hospital, Cambridge, England <i>T.G. Wreghitt, M. Hakim, J.J. Gray, S. Kucia, R. Cory-Pearce, J. Wallwork, and T.A.H. English</i>	2495
Immediate Graft Failure Treated With Partial Cardiopulmonary Bypass and Emergency Cardiac Retransplantation	<i>J.S. Morris, R.R. Lower, and S. Szentpetery</i> 2497
Clinical Heart Transplantation	<i>J.G. Losman</i> 2500
Selected Characteristics of 444 Heart Donors	<i>R.W. Evans, D.L. Manninen, and A.M. Maier</i> 2501
The Effect of Blood Pretransfusion on Orthotopic Cardiac Transplantation ...	<i>A. Keogh, D. Baron, and V. Chang</i> 2503
Late Acute Rejection After Cardiac Transplantation: Incidence and Treatment <i>H. Warnecke, S. Schueler, and R. Hetzer</i>	2504
Endocrine Response to Exercise in Cardiac Transplant Patients	<i>S. Schüler, D. Thomas, M. Thebken, U. Frei, T. Wagner, H. Warnecke, and R. Hetzer</i> 2506
Neurologic Complications After Heart Transplantation: The Influence of Immunosuppression.....	<i>H. Warnecke, S. Schueler, J. Schliffka, and R. Hetzer</i> 2510

Heterotopic Heart Transplantation

Are There Indications for Heterotopic Heart Transplantation Today?	<i>E. Becerra, D.K.C. Cooper, D. Novitzky, and B. Reichart</i> 2512
--	---

Immunosuppression

Individualized Immunosuppression in Heart Transplant Recipients.....	<i>A. Haverich, K. Frimpong-Boateng, H-J. Schäfers, Th. Wahlers, H.G. Fieguth, G. Herrmann, K. Wonigeit, and H.G. Borst</i> 2514
Determinants of Cyclosporine Nephrotoxicity Following Cardiac Transplantation <i>M. Martin, D. Packham, C. Kingswood, H. Cairns, A. Khaghani, D. Thompson, and M. Yacoub</i>	2516
Prevention of Toxic Side Effects of Cyclosporine in Heart Transplantation <i>S. Schüler, H. Warnecke, and R. Hetzer</i>	2518
Results of "Immunoconversion" From Cyclosporine to Azathioprine in Heart Transplant Recipients With Progressive Nephrotoxicity	<i>S.A. Hunt, E.B. Stinson, P.E. Oyer, M.E. Billingham, P. Gamberg, J. Miller, J.S. Schroeder, J.C. Baldwin, and N.E. Shumway</i> 2522

(Continued)

CONTENTS

(continued)

- Avoidance of Perioperative Renal Toxicity by a Modified Immunosuppression Protocol
*R.L. Kormos, A. Trento, R.L. Hardesty, B.P. Griffith, M. Thompson,
and H.T. Bahnson* 2525

Monitoring

- Acute Rejection of the Heart-Lung Allograft and Methods of Its Detection
B.P. Griffith, S.J. Durham, R.L. Hardesty, A. Trento, and I.L. Paradis 2527
- Predictors of Rejection of Cyclosporine-Treated Cardiac Allograft Recipients
*T.L. Burstain, O.H. Frazier, M.J.M. Schnee, R.H. Kerman, M.I. Lorber,
D.A. Cooley, B. Radovancevic, R. Colon, H. McAllister, B.D. Kahan,
and C.T. Van Buren* 2531
- Increase In Transferrin Receptors as a Marker for Rejection and Infection in Human
Cardiac Transplantation *K. Hoshinaga, T. Mohanakumar, N.L. Wood,
S. Szentpetery, and R.R. Lower* 2534
- Bronchoalveolar Macrophage-Lymphocyte Reactivity in Heart-Lung Transplant
Recipients *A. Zeevi, J.J. Fung, I.L. Paradis, S. Gryzan, J.H. Dauber,
R.L. Hardesty, B. Griffith, A. Trento, S. Saldman, and R.J. Duquesnoy* 2537
- Cytoimmunologic Monitoring for the Noninvasive Diagnosis of Cardiac Rejection
H.G. Fieguth, A. Haverich, H.J. Schaeffers, T. Wahlers, and J. Kemnitz 2541
- First Pass Radionuclide Scintigraphy for Long-Term Follow-up After Heart and
Heart-Lung Transplantation.... *B.M. Kemkes, H. Reichenspurner, G. Osterholzer,
M. Anthuber, N. Schad, A. Maccio, E. Erdmann, and R. Rienmüller* 2543
- Appearance of Cells Bearing the Interleukin-2 Receptor in Peripheral Blood of
Cardiac Transplant Patients and Their Correlation With Rejection Episodes
M. Coles, M. Rose, and M. Yacoub 2546
- Immunological Monitoring of Heart Allograft Recipients *O. Lungu, E. Reed,
C. Smith, E. Rose, C. Marboe, M. Hardy, K. Reemtsma, J. Fenoglio,
and N. Suciu-Foca* 2548
- The Role of Bronchoalveolar Lavage in Diagnosing Pulmonary Rejection After
Heart-Lung Transplantation..... *H-J. Schäfers, A. Haverich, L. Dammenhayn,
T. Takayama, Th. Wahlers, K. Worch, and J. Kemnitz* 2551
- Frequency Analysis of Surface Electrocardiogram and Two-Dimensional
Echocardiography for Noninvasive Diagnosis of Rejection After Heart
Transplantation *H. Reichenspurner, B.M. Kemkes, R. Haberl, Ch. Angermann,
M. Weber, G. Osterholzer, M. Anthuber, and G. Steinbeck* 2552
- Circadian Variation of Heart Rate But Not of Blood Pressure After Heart
Transplantation *G.J. Wenting, A.H. v.d. Meiracker, M.L. Simoons, E. Bos,
H.J. Ritsema v. Eck, A.J. Mann in 't Veld, W. Wiemar,
and M.A.D.H. Schalekamp* 2554

(Continued)

CONTENTS

(continued)

- Doppler Echocardiographic Indices of Diastolic Function as Markers of Acute Cardiac Rejection..... *H. Valantine, M. Fowler, L. Hatle, S. Hunt, M. Billingham, E. Stinson, and R. Popp* 2556

Biopsy Findings

- Sequential Infiltration of Class I and Class II Specific Alloreactive T Cells in Human Cardiac Allografts.....*R.J. Duquesnoy, A. Zeevi, J.J. Fung, C. Kaufman, T.R. Zerbe, B. Griffith, A. Trento, R. Kormos, and R. Hardesty* 2560
- Biopsy Assessment of Donor Hearts Prior to and During Transplantation
S. Darracott-Čanković, R. Cory-Pearce, P.G.I. Stovin, T. Wallwork, D. Wheeldon, and T.A.H. English 2564
- Sequential Studies of Major Histocompatibility Complex Antigen Expression (Common Class I and Class II Determinants, DR or DQ) in Cardiac Biopsies Following Human Cardiac Transplantation.....*A. Sutters, M. Rose, A. Khaghani, and M. Yacoub* 2566
- Myocyte Injury in Acute Cardiac Transplant Rejection and in Lymphocytic Myocarditis Is Similar and Reversible ... *N.B. Ratliff, J.L. Myles, J.T. McMahon, L. Golding, R. Hobbs, G. Rincon, R. Sterba, and R. Stewart* 2568
- Transvenous Lung Biopsy: A New Technique*M. Hakim, P. Stovin, T. English, and J. Wallwork* 2573

SUMMATION OF CLINICAL HEART TRANSPLANTATION POSTER DISCUSSIONS.....*By J.G. Losman* 2574

TRANSPLANTATION OF OTHER ORGANS

- The Importance of HLA-DR Matching in Corneal Transplant Recipients Treated With Cyclosporine A..... *H.v. Keyserlingk, G. Offermann, M. Wiederholt, and F. Hoffmann* 2576
- Use of Locally Injected Anti-T Monoclonal Antibodies in the Treatment of Acute Corneal Graft Rejection..... *G. Ippoliti and A. Fronterre* 2579
- Autotransplantation of the Adrenal Gland Using Microvascular Anastomosis
M. Matsuda 2581

(Continued)

CONTENTS

(continued)

- Clinical Small Intestinal Transplantation Using Cyclosporine A and Methylprednisolone..... *Z. Cohen, R. Silverman, G. Levy, R. Wassef, and B. Langer* 2588

SUMMATION OF CLINICAL TRANSPLANTATION— OTHER ORGANS— POSTER DISCUSSIONS.....

By C.G. Groth, O. Klintmalm, J.G. Losman, and N.L. Ascher 2591

BONE MARROW TRANSPLANTATION

CLINICAL BONE MARROW TRANSPLANTATION

- Current Status of Bone Marrow Transplantation for Severe Aplastic Anemia: A Preliminary Report From The International Bone Marrow Transplant Registry
E. Gluckman for the Advisory Committee of the International Bone Marrow Transplant Registry 2597
- European Experience of Bone Marrow Transplantation for Leukemia.....*O. Ringdén, F. Zwaan, J. Hermans, A. Gratwohl for the Leukemia Working Part of the European Group for Bone Marrow Transplantation* 2600
- A Prospective Randomized Study of Acute Graft-*v*-Host Disease in 107 Patients With Leukemia: Methotrexate/Prednisone *v* Cyclosporine A/Prednisone
S.J. Forman, K.G. Blume, R.A. Krance, P.J. Miner, G.E. Metter, L.R. Hill, M.R. O'Donnell, A.P. Nademanee, and D.S. Snyder 2605
- Marrow Transplantation for Leukemia and Aplastic Anemia: Two Controlled Trials of a Combination of Methotrexate and Cyclosporine *v* Cyclosporine Alone or Methotrexate Alone for Prophylaxis of Acute Graft-*v*-Host Disease..... *R. Storb, H.J. Deeg, J. Whitehead, V. Farewell, F.R. Appelbaum, P. Beatty, W. Bensinger, C.D. Buckner, R.A. Clift, K. Doney, J.A. Hansen, R. Hill, L.G. Lum, P. Martin, R. McGuffin, J.E. Sanders, J. Singer, P. Stewart, K.M. Sullivan, R.P. Witherspoon, and E.D. Thomas* 2608

(Continued)

CONTENTS

(continued)

- Allogeneic Bone Marrow Transplantation Without Graft-v-Host Disease: True Tolerance of Graft Against the Host Through Depletion of Donor T Lymphocytes Pregrafting in Malignant and Nonmalignant Disorders *S. Slavin, R. Or, E. Naparstek, L. Weiss, M. Mumcuoglu, Z. Weshler, H. Brautbar, G. Cividalli, M. Glikson, G. Hale, and H. Waldmann* 2614
- Graft Failure and Leukemia Relapse Following T Lymphocyte-Depleted Bone Marrow Transplants: Effect of Intensification of Immunosuppressive Conditioning *R.E. Champlin, W.G. Ho, R. Mitsuyasu, M. Burnison, P. Greenberg, G. Holly, D.W. Winston, S.A. Feig, and R.P. Gale* 2616
- Distinct Types of Donor and Recipient T Cell Clones Functionally Related to Host-v-Graft Reactivity and Autologous Remission After Bone Marrow Transplantation For Severe Aplastic Anemia *E.M. Schneider, G. Pawelec, M. Haen, G. Ehninger, P. Ostendorf, J. Kömpf, V. Schöllhorn, and P. Wernet* 2620
- Bone Marrow Transplantation for Acute Leukemia: A Preliminary Report From the International Bone Marrow Transplant Registry.... *R. Champlin, for the Advisory Committee of the International Bone Marrow Transplant Registry* 2626
- Bone Marrow Transplantation in Leukemia Using Family Donors Other Than HLA-Identical Siblings: A Preliminary Report From the International Bone Marrow Transplant Registry *M.M. Bortin, for the Advisory Committee of the International Bone Marrow Transplant Registry* 2629
- Discrimination Value of Class III and Glyoxalase Alleles for Selection of Histocompatible Bone Marrow Donors *A. Wölpl, S. F. Goldmann, Th. Eiermann, and R. Arnold* 2632
- DNA Restriction Fragment Length Analysis of the Human Class II Genes (DR, DQ) of Bone Marrow Transplant Donor-Recipient Pairs by DNA-DNA Hybridization *L. Gaidulis, K.W. Lange, G.M. Schmidt, H. Toyoda, R.B. Wallace, and K.G. Blume* 2636
- Risk Factors for Interstitial Pneumonitis Following Allogeneic Bone Marrow Transplantation for Severe Aplastic Anemia: A Preliminary Report *R.S. Weiner and K.A. Dicke for the Advisory Committee of the International Bone Marrow Transplant Registry* 2639
- Long-Term Follow-up of Patients Who Received Transplants for Aplastic Anemia or Leukemia *E. Gluckman, A. Devergie, J. Meletis, H. De Castro, P. Lehn, J.H. Bourrhis, H. Keable, M. Cavazzana, F. Varrin, D. Bombail, E. Vilmer, N. Lemerrier, N. Alby, M. Boiron, and J. Dausset* 2643
- Increased HLA-DR Compatibility Between Patients With Acute Myeloid Leukemia and Their Parents: Implications for Bone Marrow Transplantation *N.A. Carpentier and M. Jeannet* 2644
- Fibronectin Restores Defective In Vitro Proliferation of Lymphocytes From Patients After Marrow Grafting *H-G. Klingemann, M-S. Tsoi, and R. Storb* 2646

(Continued)

CONTENTS

(continued)

- Prediction of Leukemic Relapse Soon After Bone Marrow Transplantation
J.A. Tratkiewicz and J. Szer 2648
- Urinary Neopterin in Bone Marrow Recipients..... *L. Volin, S-E. Jansson,
U. Turpeinen, U-M. Pomoell, and T. Ruutu* 2651

ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE

- Acute Graft-Versus-Host Disease Following Bone Marrow Transplantation in
Humans: Prognostic Factors *M.M. Bortin, for the Advisory Committee of the
International Bone Marrow Transplant Registry* 2655
- Thalidomide Induction of Bone Marrow Transplantation Tolerance *G.B. Vogelsang,
A.D. Hess, G. Gordon, R. Brundrette, and G.W. Santos* 2658
- Acute Graft-Versus-Host Disease: Pathogenesis and Prevention With a Monoclonal
Antibody In Vivo *J. Ferrara, A. Marion, G. Murphy, and S. Burakoff* 2662
- A Class II Antigen-Specific T Cell Clone Can Suppress Graft-Versus-Host Reactivity
in Murine Allogeneic Bone Marrow Chimeras..... *C.C-Y. Shih and R.L. Truitt* 2664
- Graft-Versus-Leukemia in the Rat—The Antileukemic Efficacy of the Syngeneic and
Allogeneic Graft-Versus-Host Disease *P.J. Tutschka, S.D. Berkowitz,
S. Tuttle, and J. Klein* 2668
- Detection of Anti-non-MHC-Directed T Cell Reactivity Following In Vivo Priming
After HLA-Identical Marrow Transplantation and Following In Vitro Priming in
Limiting Dilution Cultures *C. Irlé, B. Chapuis, M. Jeannet, M. Kaestli,
N. Montandon, and B. Speck* 2674
- Haploidentical Bone Marrow Transplantation Using Soybean Agglutinin-Processed,
T-Depleted Marrow *K. Matthay, D.W. Wara, A.J. Ablin, and M.J. Cowan* 2678
- Herpes Virus Immunity and Acute Graft-Versus-Host Disease..... *J.W. Gratama,
H.T. Weiland, A.C. Hekker, T.F. Weijers, T.H. The, T. Stijnen, F.E. Zwaan,
and J.M.J.J. Vossen* 2680
- Cyclosporine-Induced Syngeneic Graft-Versus-Host Disease: Assessment of T Cell
Differentiation *A.D. Hess, G.B. Vogelsang, J. Heyd, and W.E. Beschorner* 2683
- Demonstration of Strong Classic Reactivity After Total-Body Irradiation for Bone
Marrow Transplantation. Implications for Human T-Depleted Bone Marrow
Transplantation *W. Gassmann, M.v. Kolszynski, H-U. Wottge,
and W. Müller-Ruchholtz* 2687
- Characteristics and Functions of Inflammatory Cells Isolated From Acute
Graft-Versus-Host Disease Target Organs After Bone Marrow Transplantation in
the Rat *R. Renkonen, D. Leszczynski, A. Wangen, and P. Häyry* 2689

(Continued)

CONTENTS

(continued)

Reduction of Acute Graft-Versus-Host Disease-Related Mortality and Cytotoxic Lymphocyte Induction After Pretreatment of the Recipient With Anti-Asialo GM1 Antibody in the Murine P-to-F ₁ Model.....	<i>K. Varkila and M. Hurme</i>	2690
Role of Suppressor Cells and Thymic Hormone Function in the Early and Late Phases of Murine Graft-Versus-Host Reactions	<i>Ph. Lang, S. Moritz, W. Savino, C. Rostoker, and M. Dardenne</i>	2692
Survival and Immune Recovery in Dogs Following Fetal Liver Transplantation	<i>G.R. Cain, R. E. Champlin, and R.P. Gale</i>	2695
Induction and Suppression of Graft-Versus-Host Reactivity in B6.C-H-2 Mutant Mice	<i>A. Molendijk, R.J.H.L.M. van Gurp, A. van Oudenaren, and R. Benner</i>	2698
Transfusion Effect on Graft-Versus-Host Disease and Leukemic Relapse in HLA-Matched Bone Marrow Transplantation	<i>G.C. de Gast, P.G. Beatty, D. Amos, K. Sullivan, J.E. Anderson, E.D. Thomas, and J.A. Hansen</i>	2700
T Cell Depletion of HLA and Haploidentical Marrow Reduces Graft-Versus-Host Disease But It May Impair a Graft-Versus-Leukemia Effect.....	<i>P.J. Henslee, J.S. Thompson, E.H. Romond, M.A. Doukas, M. Metcalfe, M.E. Marshall, and J.S. MacDonald</i>	2701

EXPERIMENTAL BONE MARROW TRANSPLANTATION

Hyperfractionation of Total-Body Irradiation and Engraftment of Marrow From DLA-Haploidentical Littermates	<i>L.K. Lösslein, H.J. Kolb, S. Porzolt, E. Schäffer, S. Scholz, M. Meissner, E. Holler, W. Wilmanns, and S. Thierfelder</i>	2707
Phenotypic and Functional Alterations of Recipient Lymphocytes After Transfusion of UV-Irradiated and Normal Blood—Implications for Marrow Transplantation	<i>H.J. Deeg, J. Aprile, E. Severns, J. Rajantie, E. Schmidt, R.F. Raff, K.E. Green, and R. Storb</i>	2709
Immunogenetic Analysis of Fully Allogeneic Rat Bone Marrow Transplantation	<i>E. Marquarding, J. Klempnauer, B. Steiniger, G. Filler, K. Wonigeit, and R. Pichlmayr</i>	2715
Role of Radiation-Resistant Large Granular Lymphocytes in the Rejection of Unrelated DLA-Nonidentical Marrow Grafts in Dogs.....	<i>R.F. Raff, T.P. Loughran, Jr, H.J. Deeg, J.A. Aprile, T.C. Graham, G.E. Sale, and R. Storb</i>	2718
Selective Multiplication of Hematopoietic Stem Cells For Bone Marrow Transplantation in Mice and Rhesus Monkeys	<i>G. Wagemaker</i>	2721

(Continued)

CONTENTS

(continued)

- Cell-Mediated Immune Responses in Rat Cytomegalovirus Infection.....*A.H. Esa, G.B. Vogelsang, G.R. Sandford, R. Saral, A.D. Hess, and W.H. Burns* 2726
- Lysosomal Enzyme Replacement of Neural Tissue by Allogeneic Bone Marrow Transplantation Following Total Lymphoid Irradiation in Canine Fucosidosis
R.M. Taylor, B.R.H. Farrow, G.J. Stewart, P.J. Healy, and K. Tiver 2730

BONE MARROW MANIPULATION

- Ex Vivo Depletion of Human Bone Marrow T Lymphocytes by Soybean Lectin Fractionation Followed by Treatment with an Anti-pan-T Cell (CD5) Ricin A-Chain Immunotoxin*S. Siena, S. Villa, G. Bonadonna, M. Bregni, and A.M. Gianni* 2735
- Cytogenetic Evidence of Partial Chimerism After T Cell-Depleted Allogeneic Bone Marrow Transplantation in Leukemic HLA Matched Patients*M.F. Berthéas, B. Mascret, D. Maraninchi, M. Lafage, D. Blaise, J. Fraisse, C.P. Brizard, Y. Carcassonne, and C. Mawas* 2738
- HLA-DP Matching in Allogeneic Bone Marrow Transplantation*G. Pawelec, G. Ehniger, H. Schmidt, A. Rehbein, I. Balko, and P. Wernet* 2741
- Lymphocyte Reconstitution in Children Receiving Soybean Agglutinin T-Depleted Bone Marrow Transplants*M.J. Cowan, T. McHugh, W. Smith, D. Wara, K. Matthay, A. Ablin, C. Casavant, and D. Stites* 2744
- Peripheral Blood Chemiluminescence as an Early Indicator of Successful Bone Marrow Transplantation*A. Toivanen, J. Nikoskelainen, E-M. Lilius, T.T. Salmi, K. Kätkä, T-T. Pelliniemi, A-L. Mäki, and B. Rajamäki* 2745
- Transfer of B Memory Cells to a T-Dependent Antigen in Murine Bone Marrow Transplantation*B. Tsuberi, S. Slavin, E. Kedar, and B. Leshem* 2747
- Specific Inhibition of Hybrid Resistance of B6D2F1 Mice Pretreated With Parent Strain B6 Cells: Role of a Nylon Adherent Cell Induced in the Spleen of the B6-Pretreated B6D2F1 Hybrid*K. Kosmatopoulos, S. Orbach-Arbouys, and G. Mathé* 2750
- A Murine Model for Pharmacological Marrow Purgings ...*E.A. Copelan, S.C. Johnson, M.R. Grever, and P.J. Tutschka* 2754
- Transplantation of T Cell-Depleted Bone Marrow in Histoincompatible Rabbits: Improved Engraftment and Long-Term Chimeras After the Addition or Irradiated Donor Buffy Coat Cells and Irradiated Autologous Cryopreserved Bone Marrow*A. Gratwohl, H. Baldomero, C. Nissen, and B. Speck* 2756
- Effector Cells of Graft-Versus-Host Disease, Host Resistance, and the Graft-Versus-Leukemia Effect: Summary of a Workshop on Bone Marrow Transplantation*O. Rigdén, H.J. Deeg, W. Beschorner, and S. Slavin* 2758

(Continued)

CONTENTS

(continued)

PART IV
TRANSPLANTATION TODAY
AND TOMORROW

Immunology and Immunogenetics Synopsis	<i>M. Simonsen</i>	2765
Summary: Immunosuppression	<i>C.B. Carpenter</i>	2770
Critical Issues in Bone Marrow Transplantation	<i>R. Storb</i>	2774
Clinical Organ Transplantation.....	<i>A.G.R. Sheil</i>	2782
Author Index		2787
Subject Index		2807

Incidence of Fistulas Following Human Pancreas Transplantation—Positive Influence of Reabsorption of Pancreatic Secretions by the Peritoneum

W-D. Illner, Th. Gottwald, D. Abendroth, and W. Land

THERE IS EVIDENCE suggesting that transplantation of the pancreas is the only approach to a curative treatment of type I diabetes.¹⁻³ The results of this surgical method improved during the last years with the new agent cyclosporine (Cs) and better patient management. In 1982 the one-year-survival-rate of pancreas grafts was about 20% worldwide, whereas in 1984 it had risen to 38%.⁴ In spite of this improvement, pancreas transplantation is still less successful than transplantation of other organs. One major reason for this fact is the difficulty in optimal handling of exocrine secretion.

Since 1979 the Munich group has been using prolamine (Ethibloc, Ethicon) in a consecutive series of 56 patients. Despite occlusion of the duct, a high incidence of pancreatic fistulas occurred, implicating the risk of a secondary bacterial contamination.

By modifying our surgical technique⁵ to a strictly intraperitoneal placement of the pancreas graft, we wanted to know whether the resorption capacity of the peritoneum would provide a reduction of the incidence of fistulas.

PATIENTS AND METHODS

Fifty-two of those 56 patients received a pancreas and a kidney graft simultaneously. In these 52 patients we evaluated fistula incidence, frequency of reintervention, and graft loss rate secondary to an infected fistula. According to the different surgical techniques there are two groups: group 1 (n = 25), in which the segmental pancreas graft was placed partially extra- and intraperitoneally⁶; and group 2 (n = 27), in which the pancreas graft was placed strictly intraperitoneally along the ascending colon. The peritoneal cavity was continuously irrigated with saline solution over the first postoperative days.

RESULTS

The incidence of fistulas in group 1 was 52% compared to 44% in group 2. The rate of secondary bacterial contamination of a fistula with subsequent surgical reinterventions showed no significant difference between both groups (2 v 2.5). In five patients in group 1 the rescue of an infected fistula failed, compared to two cases in group 2.

DISCUSSION

Our working hypothesis claimed that reabsorption of residual exocrine secretion by the peritoneum would reduce the incidence of fistulas. This could not be confirmed, because neither the fistula incidence rate nor the reoperating rate were statistically different. Specific and specific defense mechanisms of the peritoneum seem to have a positive effect against secondary infection of a fistula. Graft loss due to a fistula occurred in only 8% of patients treated with the modified technique (group 2) compared to 20% of the patients in group 1.

The improvement of graft survival rate (15% difference between group 1 and group 2) is probably based on defense mechanisms of the peritoneum. Therefore, we will continue to use the strictly intraperitoneal placement of duct-occluded pancreas grafts.

From the Transplantation Centre, Department of Surgery, Klinikum Grosshadern University of Munich.

Address reprint requests to Dr W-D. Illner, Transplantation Centre, Klinikum Grosshadern, Marchionistr. 15, 8000 München 70, FRG.

*© 1987 by Grune & Stratton, Inc.
0041-1345/87/1901-0877\$03.00/0*

REFERENCES

1. Sutherland DER, Najarian JS: In Brooks JR (ed): *Surgery of the Pancreas*. Philadelphia, Saunders, 1983, p 424
2. Landgraf R, Abendroth D, Land W: *Horm Metab Res* 13:57, 1983 (suppl)
3. Dubernard JM, Traeger J, Possa G, et al: *Transplant Proc* 15:1318, 1983
4. Sutherland DER: *World J Surg* 8:270, 1984
5. Land W, von Liebe S, Höpp H, et al: *Chir Prax* 27:15, 1980
6. Dubernard JM, Traeger J, Neyra P, et al: *Surgery* 84:633, 1978